CONCORD, Calif.–(BUSINESS WIRE)–Cerus Corporation (Nasdaq: CERS) today announced positive topline results for ReCePI, a pivotal Phase 3 clinical trial of pathogen reduced INTERCEPT Red Blood Cells (INTERCEPT RBCs) transfused to complex cardiac surgery patients. The trial met its primary efficacy endpoint, demonstrating non-inferiority for INTERCEPT RBCs compared to conventional RBCs as measured by the incidence of acute kidney injury (AKI) following transfusion of study RBCs. AKI is a sensiti
Other News
PECA Labs Receives Expanded CE Mark for exGraft Family of Vascular Grafts, Allowing for Expandability Designed to Match Growth or Help Avoid Restenosis
PITTSBURGH–(BUSINESS WIRE)–PECA Labs, a medical device company reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last, has received an additional CE Mark for its exGraft family of vascular grafts, expanding its on-label use. exGraft vascular grafts are intended for use as vascular prostheses for replacement or bypass of diseased or injured vessels, and with the new clearance, exGraft now includes instructions for post-
Merit Medical Systems to Announce First Quarter 2024 Results on April 30, 2024
SOUTH JORDAN, Utah, March 18, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2024, after the close of the stock market on Tuesday, April 30, 2024. Merit will hold its investor conference call on the same day (Tuesday, April 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at merit.com. ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves client hospitals worldwide with a domestic and international sales force and clinical support team totaling more than 700 individuals. Merit employs approximately 7,000 people worldwide. Contacts: PR/Media Inquiries:Teresa Johnson Merit MedicalInvestor Inquiries:Mike Piccinino, CFA, IRCWestwicke – ICR+1-801-208-4295+1-443-213-0509tjohnson@merit.commike.piccinino@westwicke.com
Nanox to Report Fourth Quarter and Fiscal Year 2023 Financial Results on April 1, 2024
PETAH TIKVA, Israel, March 18, 2024 (GLOBE NEWSWIRE) — NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will report its financial results for the quarter and fiscal year ended December 31, 2023, before market open on Monday, April 1, 2024. Erez Meltzer, Chief Executive Officer, and Ran Daniel, Chief Financial Officer, will host a conference call to review these results and provide a business update beginning at 8:30 a.m. ET. Interested parties may register for the conference call using the following link: Nanox Q4 Earnings Call Registration. You may access the live webcast of the conference call by using the following link: Nanox Q4 Earnings Call Webcast. The link will also be posted in the Investor Relations section of the Nanox website at Events and Presentations. About Nanox Nanox (NASDAQ: NNOX) is focused on applying its proprietary medical imaging technology and solutions to make diagnostic medicine more accessible and affordable across the globe. Nanox’s vision is to increase access, reduce costs and enhance the efficiency of routine medical imaging technology and processes, in order to improve early detection and treatment, which Nanox believes is key to helping people achieve better health outcomes, and, ultimately, to save lives. The Nanox ecosystem includes Nanox.ARC— a multi-source Digital Tomosynthesis system that is cost-effective and user-friendly; an AI-based suite of algorithms that augment the readings of routine CT imaging to highlight early signs often related to chronic disease (Nanox AI); a cloud-based infrastructure (Nanox.CLOUD); and a proprietary decentralized marketplace, through Nanox’s subsidiary, USARAD Holdings Inc., that provides remote access to radiology and cardiology experts; and a comprehensive teleradiology services platform (Nanox.MARKETPLACE). Together, Nanox’s products and services create a worldwide, innovative and comprehensive solution that connects medical imaging solutions, from scan to diagnosis. For more information, please visit www.nanox.vision. Contacts Media Contact: Ben ShannonICR WestwickeNanoxPR@icrinc.com Investor Contact: Mike CavanaughICR Westwickemike.cavanaugh@westwicke.com
Aquedeon Medical Announces First Patient Enrolled in the IDE Study of Duett(TM) Vascular Graft System
SUNNYVALE, Calif., March 18, 2024 /PRNewswire/ — Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone with initiation of its investigational device exemption (IDE)…
Dr. Ameer Hassan Establishes Distinctive Scholarship to Foster Excellence in Medical Education
HARLINGEN, Texas, March 15, 2024 /PRNewswire/ — Dr. Ameer Hassan, a distinguished figure in the realm of neurology and neuroendovascular medicine, proudly announces the establishment of the Dr. Ameer Hassan Scholarship for Medical Students. This prestigious scholarship, available…
Acticor Biotech Launches a Capital Increase of a Minimum of 7 Million Euros
Capital increase consisting of an offer to qualified investors, categories of investors and individual investors via the PrimaryBid platform Subscription commitments from existing shareholders and new investors for a total of around 6.46 M€ Issue price of the new shares of €3.13 per share Closing of the Primary Bid and […]
Tampa General Hospital Employs New Ultrasound Therapy Designed to Treat Life-Threatening Hypertension
The hospital is the first in the area to use a new FDA-approved device for patients suffering from uncontrolled high blood pressure. TAMPA, Fla., March 14, 2024 /PRNewswire/ — Doctors with the Tampa General Hospital (TGH) Heart & Vascular Institute are the first in the region to use an…
Endologix to Present at Upcoming LSI US ’24 Emerging Medtech Summit
IRVINE, Calif.–(BUSINESS WIRE)–Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, today announced that Matt Thompson, President and CEO, will present at the Life Science Intelligence (LSI) USA ’24 Emerging Medtech Summit. Scheduled for March 20, 2024, at 10:55 am PT on Track 3, Thompson will offer insights into the company’s innovative portfolio and its impact on vascular disease trea
PrepMD Welcomes Jack Collier as New Chief Technology Officer
BRAINTREE, Mass., March 13, 2024 /PRNewswire/ — PrepMD, the premier provider of cardiac healthcare solutions, announces the appointment of Jack Collier as its new Chief Technology Officer (CTO). Jack Collier, with a distinguished career as the Co-Founder and former CTO of Atlantis…
Recent
MicroTransponder Joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation
New Minimally Invasive Therapy at MemorialCare Heart & Vascular Institute Reduces Cardiovascular Mortality by Nearly 30% in Patients with Resistant Hypertension
Zylox-Tonbridge to Acquire Equity Interest in A European Medical Device Company to Accelerate Expansion in the Global MedTech Market
Popular
- No commented posts yet